MTOR and Familial prostate cancer: Although preclinical studies show mTOR inhibitors reverting prostatic neoplasia and reducing cell growth and proliferation (Morgan et al, 2009), the clinical experience of mTOR inhibition in men with castrate-resistant prostate cancer has been disappointing.